Organon & Co | OGN - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Celltrion KRW 119.22B 21.46B 2026-03
Cspc Pharmaceutical CNY 5.91B 512.77M 2025-12
Deva Holding AS TRY 1.35B 178.26M 2023-09
Dianthus Therapeutics USD 47M 22.83M 2026-03
Divis Laboratories Ltd INR 20.17B 1.85B 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Kangmei Pharma CNY 1.09B 304.02M 2026-03
Knight Therapeutics CAD 126.9M 8.29M 2025-12
Laboratorios Farma EUR 313.62M 17.98M 2023-12
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 21.61M 11.59M 2025-12
Merck USD 18.17B 8.01B 2026-03
Neuren Pharmaceuticals AUD 25.23M 16.54M 2025-12
Novartis USD 9.29B 507M 2026-03
Organigram Holdings CAD 69.59M 14.08M 2026-03
Organon & Co USD 903M 387M 2026-03
Ovoca Bio EUR 1.16M 4.48M 2025-06
Pharma Mar EUR 42.28M 4.59M 2026-03
Qiagen NV USD 375.69M 42.85M 2026-03
Sartorius EUR 747.8M 9.4M 2026-06
Sino Biopharmaceutical CNY 12.39B 1.26B 2025-06
Tilray USD 237.52M 17.34M 2025-09
Zealand Pharma A/S 775.97M 265.08M 2025-12